156 related articles for article (PubMed ID: 34490122)
1. Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.
Rolles B; Gorgulho J; Tometten M; Roderburg C; Vieri M; Abels A; Vucur M; Heymann F; Tacke F; Brümmendorf TH; Luedde T; Beier F; Loosen SH
Front Oncol; 2021; 11():729207. PubMed ID: 34490122
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies.
Gorgulho J; Roderburg C; Heymann F; Schulze-Hagen M; Beier F; Vucur M; Kather JN; Laleh NG; Tacke F; Brümmendorf TH; Luedde T; Loosen SH
Int J Cancer; 2021 Sep; 149(5):1189-1198. PubMed ID: 33890289
[TBL] [Abstract][Full Text] [Related]
3. Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity.
Yoon SY; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Acta Haematol; 2007; 118(1):30-7. PubMed ID: 17429195
[TBL] [Abstract][Full Text] [Related]
4. Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
Loosen SH; van den Bosch V; Gorgulho J; Schulze-Hagen M; Kandler J; Jördens MS; Tacke F; Loberg C; Antoch G; Brümmendorf T; Neumann UP; Kuhl C; Luedde T; Roderburg C
J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33806224
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Jessurun CAC; Vos JAM; Limpens J; Luiten RM
Front Oncol; 2017; 7():233. PubMed ID: 29034210
[TBL] [Abstract][Full Text] [Related]
6. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
Loosen SH; Gorgulho J; Jördens MS; Schulze-Hagen M; Beier F; Vucur M; Schneider AT; Koppe C; Mertens A; Kather JN; Tacke F; Keitel V; Brümmendorf TH; Roderburg C; Luedde T
Front Oncol; 2021; 11():646883. PubMed ID: 33869041
[TBL] [Abstract][Full Text] [Related]
7. Telomeres and prognosis in patients with chronic lymphocytic leukaemia.
Sellmann L; de Beer D; Bartels M; Opalka B; Nückel H; Dührsen U; Dürig J; Seifert M; Siemer D; Küppers R; Baerlocher GM; Röth A
Int J Hematol; 2011 Jan; 93(1):74-82. PubMed ID: 21203871
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade.
Gorgulho J; Roderburg C; Beier F; Bokemeyer C; Brümmendorf TH; Luedde T; Loosen SH
Front Immunol; 2023; 14():1206953. PubMed ID: 37705980
[TBL] [Abstract][Full Text] [Related]
10. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
11. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
Buder-Bakhaya K; Hassel JC
Front Immunol; 2018; 9():1474. PubMed ID: 30002656
[TBL] [Abstract][Full Text] [Related]
13. Correlates of telomere length shortening in peripheral leukocytes of HIV-infected individuals and association with leukoaraiosis.
Minami R; Takahama S; Yamamoto M
PLoS One; 2019; 14(6):e0218996. PubMed ID: 31246986
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
Front Oncol; 2020; 10():572853. PubMed ID: 33163403
[TBL] [Abstract][Full Text] [Related]
15. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
16. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
17. Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer.
Russo A; Modica F; Guarrera S; Fiorito G; Pardini B; Viberti C; Allione A; Critelli R; Bosio A; Casetta G; Cucchiarale G; Destefanis P; Gontero P; Rolle L; Zitella A; Fontana D; Frea B; Vineis P; Sacerdote C; Matullo G
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2439-46. PubMed ID: 25234236
[TBL] [Abstract][Full Text] [Related]
18. Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.
Gorgulho J; Roderburg C; Beier F; Bokemeyer C; Brümmendorf TH; Loosen SH; Luedde T
Br J Cancer; 2024 Apr; 130(6):1013-1022. PubMed ID: 38233492
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
20. Short telomere length in peripheral blood leukocyte predicts poor prognosis and indicates an immunosuppressive phenotype in gastric cancer patients.
Qu F; Li R; He X; Li Q; Xie S; Gong L; Ji G; Lu J; Bao G
Mol Oncol; 2015 Mar; 9(3):727-39. PubMed ID: 25515040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
